All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Omega Funds
Deal Size: $62.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 07, 2021
Details:
Proceeds from the financing will be used to advance taladegib, an inhibitor of the Hedgehog pathway, into two Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis (IPF) in 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FP-025
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FP-025
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 24, 2020
Details:
The proceeds of the Public Offering will be used for supporting Foresee’s existing drug research and development programs – such as FP-025, for which a Phase II/III clinical trial IND application was recently submitted to the FDA for the treatment of ARDS in COVID-19 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Larazotide Acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AT-1001
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: European Biomedical Research Institute of Salerno
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 21, 2020
Details:
EBRIS and 9 Meters have entered into a material transfer agreement for drug supply sufficient to initiate and complete a Phase 1 study in Australia in 2021 to assess the safety and tolerability of larazotide when delivered directly to the lungs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VR588
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: VR588
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Vectura Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 30, 2020
Details:
This agreement provides an opportunity for Vectura to realise value from its historical research and investment in VR588, whilst expanding its CDMO development services portfolio by supporting the product's further development with Kinaset.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBT-877
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BBT-877
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination November 09, 2020
Details:
Bridge Biotherapeutics and Boehringer Ingelheim have mutually agreed on the termination of the Collaboration and License Agreement entered into in July 2019 to develop BBT-877 for the treatment of idiopathic pulmonary fibrosis and various fibrotic diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ETD002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ETD002
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: $96.8 milion
Deal Type: Acquisition October 07, 2020
Details:
Enterprise Therapeutics' TMEM16A portfolio includes ETD002, first of its compounds to hit clinical stage. In pre-clinical models the compound has been found to enhances the activity of TMEM16A.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Itolizumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EQ001
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
These findings suggest the CD6-ALCAM pathway may contribute in multiple ways to asthma pathology. These data support Equillium’s ongoing clinical development of itolizumab for the treatment of patients with moderateto-severe uncontrolled asthma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATYR1923
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KRP-R120
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: KYORIN PHARMACEUTICAL CO LTD
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
Kyorin Holdings has initiated clinical development in Japan for aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan) following the Pharmaceutical and Medical Devices Agency (PMDA) review of its Clinical Trial Notification (CTN) submission.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ARINA-1
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ARINA-1
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: White Rock Capital Management
Deal Size: $8.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 18, 2020
Details:
Funds to be used for the development and clinical programs associated with Renovion's lead therapeutic candidate ARINA-1. ARINA-1 is a nebulized therapy developed to improve mucus clearance and decrease inflammation in patients diagnosed with chronic lung disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TRV027
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Trevena
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2020
Details:
Collaboration to evaluate the potential of TRV027, a novel AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome (ARDS) in COVID-19 patients.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
